Below are the Nasdaq 100 companies that are within 20% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models. Although theses companies are very risky, they provide significant opportunity to outperform the market in the coming year.
Symbol | Name | Price | P/E | EPS | Yield | P/B | % From Low |
CELG | Celgene Corp | $51.29 | 27.28 | 1.88 | 0 | 4.42 | 6.81% |
CEPH | Cephalon | $59.96 | 11.2 | 5.35 | 0 | 1.81 | 9.02% |
QGEN | Qiagen N.V. | $18.48 | 29.06 | 0.64 | 0 | 1.77 | 9.61% |
AMGN | Amgen | $55.20 | 11.52 | 4.79 | 0 | 2.16 | 9.83% |
TEVA | Teva Pharma. | $54.10 | 16.65 | 3.25 | 1.30% | 2.26 | 15.13% |
CSCO | Cisco Systems | $22.05 | 16.09 | 1.37 | 0 | 2.73 | 16.05% |
ATVI | Activision | $11.74 | 39.93 | 0.29 | 1.30% | 1.31 | 17.52% |
URBN | Urban Outfitters | $34.76 | 21.6 | 1.61 | 0 | 4.21 | 19.74% |
The following is the order that we think the watch list companies might perform over the next year (from best to worst on a percentage basis) and our thoughts on the reasons why.
-
Celgene (CELG): Celgene has no debt, strong earnings growth, while the book value has increased nearly 50% in the last 5 years.
-
Urban Outfitter (URBN): This clothing retailer has no debt and a book value increase of nearly 24% in the last ten years. We do not expect the same growth rate of the book going forward since the fashion industry is so fickle.
-
Teva Pharmaceutical (TEVA): Although saddled with some debt, this Israeli based pharmaceutical company is undervalued on a cash flow basis by 23% according to Value Line.
-
Cisco Systems (CSCO): One drawback for Cisco Systems is its management team which appears highly compensated for lackluster performance in the stock price. Despite this concern, CSCO has reduced the shares outstanding by nearly 23% since 2001. However, this may be a result of the large amount of debt that has been taken on since 2006. Such borrowing may be prudent given the current low interest rate environment. The book value for CSCO has grown almost 12% annually over the last 10 years.
-
Amgen (AMGN): Amgen has reduced the shares outstanding by nearly 23% since 2002. Unfortunately, the share reduction has been at the expense of a nearly 250% increase of long-term debt in the same period of time. According to Value Line dated December 17, 2010, AMGN normally trades around 12 times cash flow. Using the most conservative numbers provided by Value Line, AMGN should be selling at $72 a share instead of the current price of $55.20.
-
Cephalon (CEPH): There is a severe disconnect with Cephalon and the stock market. CEPH shares trade at less than the 2001 high. According to Value Line, the annualized growth rate of the book value over the same period has been 26%. The company’s debt has remained relatively steady while the number of shares outstanding has grown by “only” 7.6% annually. CEPH should be selling for at least $76 if the numbers on this company are accurate.
Watch List Performance Review
In our ongoing review of the Nasdaq 100 Watch List, we have taken the stocks from our list of February 7, 2010 (article here) and have checked their performance one year later. The companies on that list are provided below with the closing price for February 5, 2010 and February 4, 2011.
Symbol | Name | 2010 | 2011 | % change | |||||||
SRCL | Stericycle | $52.00 | $83.63 | 60.83% | |||||||
QCOM | QUALCOMM | $38.04 | $55.23 | 45.19% | |||||||
FSLR | First Solar | $114.19 | $157.94 | 38.31% | |||||||
GENZ | Genzyme | $55.17 | $73.40 | 33.04% | |||||||
ATVI | Activision Blizzard | $10.21 | $11.74 | 14.99% | |||||||
ERTS | Electronic Arts | $17.26 | $18.23 | 5.62% | |||||||
GILD | Gilead Sciences | $46.38 | $38.79 | -16.36% | |||||||
APOL | Apollo Group | $59.93 | $42.14 | -29.68% | |||||||
Average | 18.99% |